Latest Healthcare News

Anteris Technologies has completed a $90 million strategic investment from Medtronic as part of a $320 million capital raise, advancing its DurAVR transcatheter heart valve towards global commercialisation and pivotal clinical trials.

Rhythm Biosciences has begun commercialising its blood-based colorectal cancer test, ColoSTAT®, following key accreditations and validation. The company also secured a strategic partnership with NHS England and expanded its geneType™ platform globally.

Anteris Technologies has closed a $320 million capital raise, combining a $230 million public offering and a strategic private placement with Medtronic, to advance its DurAVR heart valve clinical trials and manufacturing growth.

Osteopore Limited has secured an exclusive agreement with MontsMed Hong Kong to introduce its innovative 3D-printed orthopaedic implants into Hong Kong, positioning itself strategically within the Greater Bay Area’s burgeoning medical market.

Invex Therapeutics reports promising new data from its collaboration with Tessara Therapeutics on Exenatide’s potential in Alzheimer’s disease, alongside significant board changes and a solid cash position at quarter’s end.

Anteris Technologies Global Corp. has launched a $230 million equity offering alongside an $84 million private placement with Medtronic’s subsidiary, aiming to accelerate clinical trials and scale manufacturing of its innovative DurAVR Transcatheter Heart Valve.

Excite Technology Services has reported a record-breaking quarter with $9.2 million in customer receipts, marking a 125% increase year-over-year, alongside positive operating cash flow and strategic contract wins.

AMCIL Limited reported a 14.8% increase in half-year profit to $4.1 million, maintaining its interim dividend amid a portfolio return that lagged the ASX 200 benchmark.

Osteopore Limited has inked a three-year exclusive distribution agreement with MontsMed to introduce its advanced orthopaedic trauma reconstruction products into Hong Kong, positioning itself strategically within the Greater Bay Area.

Cogstate Ltd has reported a remarkable 105% surge in clinical trial sales contracts for the first half of 2026, surpassing revenue guidance and signalling a more diversified and resilient business model.

Australian Foundation Investment Company reports a 4.6% decline in half-year profit but sustains its interim dividend with a special payout, while portfolio returns lag the benchmark.

Imricor Medical Systems has secured Virginia Commonwealth University Health as the third US site for its VISABL-AFL clinical trial, advancing its FDA approval pathway for MRI-guided cardiac ablation technology.